Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Vertex Pharmaceuticals Incorporated    VRTX

Delayed Quote. Delayed  - 12/07 09:59:59 pm
75.32 USD   -3.58%
12/02 VERTEX PHARMACE : VRTX) Files An 8-K Departure of Directors or Certa..
11/29 NASDAQ 100 MOVE : Bmrn, nflx
11/11 NASDAQ 100 MOVE : Alxn, nvda
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Vertex Pharmaceuticals Incorporated : VRTX, OSTK, and GRPN added to Nasdaq Gainers Watch List at GSR

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/19/2013 | 05:40pm CET

New York, NY -- (ACCESSWIRE) -- 04/19/2013 -- Growing Stock Report initiates a NASDAQ Gainers Weekly Watch List adding Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Overstock.com Inc. (NASDAQ:OSTK), Groupon, Inc. (NASDAQ:GRPN), BioScrip Inc. (NASDAQ:BIOS) and Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX).

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) a company that engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases is currently up (+55.57%) on 13,455,455 shares traded after announcing statistically significant results from a phase 2 study for the treatment of cystic fibrosis. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is currently up (+134.49%) from its recent 52-week low which has prompted Growing Stock Report to add the stock to their NASDAQ Gainers Watch List.

To see what other Investors are saying about Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Click Here: http://www.growingstockreport.com/Survey.aspx?stock=VRTX&SubId=AW

Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX) a development-stage specialty pharmaceutical company is currently up (+24.10%) on 1,789,829 shares traded after Coverage was initiated on Catalyst Pharmaceutical by Aegis Capital. Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX) is currently up (+105.41%) from its recent 52-week low which has prompted Growing Stock Report to add the stock to their NASDAQ Gainers Watch List.

To see what other Investors are saying about Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX)

Click Here: http://www.growingstockreport.com/Survey.aspx?stock=CPRX&SubId=AW

Also mentioned in Growing Stock Report's Nasdaq Gainers Watch List and Investor Poll was: Overstock.com Inc. (NASDAQ:OSTK), Groupon, Inc. (NASDAQ:GRPN), Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX) and BioScrip Inc. (NASDAQ:BIOS).

To see what other Investors are saying about: OSTK, GRPN, CPRX and BIOS

Click Here: http://www.growingstockreport.com/PR.aspx?stock=OSTK-GRPN-CPRX-BIOS&SubID=AW

GrowingStockReport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.

Through a vast network of IR professionals GrowingStockReport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.GrowingStockReport.com

Disclosure: GrowingStockReport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit GrowingStockReport.com website, for complete risks and disclosures.

Contact Info:
Growing Stock Report
editor@GrowingStockReport.com


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on VERTEX PHARMACEUTICALS INC
12/02 VERTEX PHARMACEUTICALS INCORPORATED : VRTX) Files An 8-K Departure of Directors..
12/02 VERTEX PHARMACEUTICALS INC / MA : Change in Directors or Principal Officers (for..
11/29 NASDAQ 100 MOVERS : Bmrn, nflx
11/17 VERTEX PHARMACEUTICALS INCORPORATED : Positive Phase 3 Study of ORKAMBI® in Chil..
11/14 VERTEX PHARMACEUTICALS INCORPORATED : Assigned Patent
11/11 NASDAQ 100 MOVERS : Alxn, nvda
11/10 VERTEX PHARMACEUTICALS INCORPORATED : to Present at the Credit Suisse Healthcare..
11/09 VERTEX PHARMACEUTICALS INCORPORATED : (VRTX) Pops 11.92% for November 09
11/07 VERTEX PHARMACEUTICALS INCORPORATED : Positive Phase 3 Study of ORKAMBI® in Chil..
11/03 VERTEX PHARMACEUTICALS INCORPORATED : Announces Planned Initiation of Phase 2 St..
More news
Sector news : Bio Therapeutic Drugs
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
11/30 ACTELION : Rejecting J&J could leave Actelion with 'lot of explaining to do'
11/28 Actelion's ambitious independent-minded CEO will drive up takeover price
11/26DJWHAT'S NEWS : Business & Finance -- WSJ
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
12/02 Vertex promotes two execs
11/30 Cystic Fibrosis Spotlight Turns To Galapagos
11/29 Barclays softens views on five biopharma firms
11/29 Galapagos launches early-stage study of corrector drug for cystic fibrosis, e..
11/28 Nivalis' cystic fibrosis candidate cavosonstat flunks mid-stage study; shares..
Advertisement
Financials ($)
Sales 2016 1 693 M
EBIT 2016 182 M
Net income 2016 -134 M
Finance 2016 185 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017 77,58
EV / Sales 2016 11,3x
EV / Sales 2017 8,61x
Capitalization 19 376 M
More Financials
Chart VERTEX PHARMACEUTICALS INC
Duration : Period :
Vertex Pharmaceuticals Inc Technical Analysis Chart | VRTX | US92532F1003 | 4-Traders
Full-screen chart
Technical analysis trends VERTEX PHARMACEUT...
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 102 $
Spread / Average Target 30%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Jeffrey M. Leiden Chairman, President & Chief Executive Officer
Simon Bedson SVP & GM-International Commercial Operations
Ian F. Smith Chief Financial Officer & Executive Vice President
Jeffrey A. Chodakewitz Chief Medical Officer & Executive Vice President
David Matthew Altshuler Chief Scientific Officer & EVP-Global Research
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
VERTEX PHARMACEUTICALS..-40.14%19 376
AMGEN, INC.-13.02%107 951
GILEAD SCIENCES, INC.-28.08%95 476
CELGENE CORPORATION-5.93%91 001
REGENERON PHARMACEUTIC..-33.32%38 913
ACTELION LTD45.20%21 783
More Results